[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100387420":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":37,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"King's College Hospital NHS Trust","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Neuroendocrine neoplasms (tumours)",null,"Patients with a diagnosis of neuroendocrine neoplasm who are due to undergo one of the following treatments: chemotherapy, everolimus, sunitinib, somatostatin analogues, peptide receptor targeted therapy, embolization\u002F ablative therapies or surgery.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Raj Srirajaskanthan","CONTACT","0203 299 3255","r.srirajaskanthan@nhs.net",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"King's College Hospital","RECRUITING","London","SE5 9RS","United Kingdom","UK",{"type":27,"coordinates":28},"Point",[29,30],-0.12574,51.50853,{"lat":30,"lon":29},[33],{"name":14,"role":15,"phone":34,"phoneExt":10,"email":17},"02032996044",{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[38,41],{"name":39,"class":40},"Ampersand Health Ltd","UNKNOWN",{"name":42,"class":40},"Neuroendocrine Cancer UK","100387420","mobile-application-to-collect-pro-data-in-net-patients-100387420",false,"NCT04324502","Mobile Application to Collect PRO Data in NET Patients","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of a NET\n* Planned treatment for NET\n* Able to give informed consent\n* Able to understand the language of the questionnaires\n* A minimum expected survival of 6 months\n* All performance status is acceptable\n* 18 years of age or over\n\nExclusion Criteria:\n\n* Concurrent malignancies for which they are undergoing treatment\n* No smartphone \u002F device\n* Any physical, psychological or comprehension problems that prevents completion of questionnaires.","ALL","18 Years",{"count":52,"type":53},2000,"ESTIMATED","OBSERVATIONAL","Observational trial to assess the feasibility of monitoring patient reporting symptoms via mobile devices",[57],"Neuroendocrine Neoplasms (Tumours)","2020-11-05",{"date":60,"type":61},"2020-11-09","ACTUAL",{"date":63,"type":61},"2020-07-20",{"date":65,"type":53},"2026-07",{"name":5,"class":6},1]